Salute e Benessere
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
To learn more about Hansa Biopharma see the latest Corporate Presentation here . The latest investor presentation can be viewed here .
Evan Ballantyne ,
ir@hansabiopharma.com
Stephanie Kenney,
media@hansabiopharma.com
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden , and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn .
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/hansa-biopharma-to-participate-in-hc-wainwright-26th-annual-global-investment-conference-302239226.html